← Leaderboards
Patricia Ann Shi
Icahn School Of Medicine At Mount Sinai
$3,299,774
Attributed
$3,299,774
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $579.5K · FY2008–24$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,099,774 · 4
FDA$200,000 · 1
By mechanism
P01$2,315,164 · 1
K23$654,798 · 1
R01$200,000 · 1
R21$128,100 · 1
M01$1,712 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Nadejda Mincheva Tsankova$4,976,869
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaHemoglobinopathiesLaboratoriesMouse ModelHemolysisEnrollmentBaseResearch PersonnelUnited StatesSickle CellTransfusionStudy SubjectPeripheral BloodUnited States National Institutes Of HealthPersonsLogisticsProgramsFreezingAffectDoseCollectionCell CommunicationAcute PainClinical Application
Grant awards (13)
Human Subjects Core$451,449
P01 · FY2024 · HL · contact PI
Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients$128,100
R21 · FY2024 · HL · contact PI
Human Subjects Core$460,661
P01 · FY2023 · HL · contact PI
Human Subjects Core$460,661
P01 · FY2022 · HL · contact PI
Human Subjects Core$460,661
P01 · FY2021 · HL · contact PI
Human Subjects Core$481,732
P01 · FY2020 · HL · contact PI
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin$126,179
K23 · FY2013 · HL · contact PI
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin$126,179
K23 · FY2012 · HL · contact PI
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin$134,200
K23 · FY2010 · HL · contact PI
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin$134,200
K23 · FY2009 · HL · contact PI
TREATMENT POOR HEMATOPOIETIC STEM CELL MOBILIZATION WITH G-CSF & ALBUTEROL$1,712
M01 · FY2009 · RR · contact PI
Phase 1-2 trial of Gamunex (intravenous gammaglobulin) for Sickle Cell Acute Pain$200,000
R01 · FY2008 · FD · contact PI
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin$134,040
K23 · FY2008 · HL · contact PI